Male hormonal contraception: Potential risks and benefits

被引:0
|
作者
Niloufar Ilani
Ronald S. Swerdloff
Christina Wang
机构
[1] Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute,Division of Endocrinology, Department of Medicine
[2] General Clinical Research Center,undefined
[3] Harbor-UCLA Medical Center,undefined
关键词
Testosterone; Progestin; Male contraception; Family planning;
D O I
暂无
中图分类号
学科分类号
摘要
An effective, safe, reversible, and acceptable method of contraception is an important component of reproductive health and provides the opportunity of shared responsibility for family planning for both partners. Female hormonal contraceptives have been proven to be safe, reversible, available and widely acceptable by different populations. In contrast, male hormonal contraception, despite significant progress showing contraceptive efficacy comparable to female hormonal methods during last three decades, has not yet led to an approved product. Safety of a pharmaceutical product is an appropriate concern but the majority of male hormonal contraceptive clinical trials have not reported significant short term safety concerns. While the absence of serious adverse effects is encouraging, the studies have been designed for efficacy endpoints not long term safety. In this review we summarize potential risks and benefits of putative male hormonal contraceptives on reproductive and non-reproductive organs. While the review covers what we believe will be the likely class of drugs used for male hormonal contraception a true assessment of long term risks and benefits cannot be achieved without an available product.
引用
收藏
相关论文
共 50 条
  • [1] Male hormonal contraception: Potential risks and benefits
    Ilani, Niloufar
    Swerdloff, Ronald S.
    Wang, Christina
    [J]. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2011, 12 (02): : 107 - 117
  • [2] Transdermal hormonal contraception: benefits and risks
    Burkman, Ronald T.
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007, 197 (02) : 134.e1 - 134.e6
  • [3] Weighing the Risks and Benefits of Hormonal Contraception
    Peachman, Rachel Rabldn
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (11): : 1083 - 1084
  • [4] RISKS AND BENEFITS OF ORAL HORMONAL CONTRACEPTION
    Simunic, Velimir
    [J]. ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2009, 78 : 1 - 3
  • [5] HORMONAL CONTRACEPTION - BENEFITS VERSUS RISKS
    GOLDZIEHER, JW
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1987, 157 (04) : 1023 - 1028
  • [6] Hormonal Male Contraception
    Giwercman, Aleksander
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (24) : 2770 - 2774
  • [7] Male Hormonal Contraception
    Armillotta, F.
    Cerpolini, S.
    Berra, M.
    Matteucci, C.
    Perrone, A. M.
    Pelusi, G.
    Meriggiola, M. C.
    [J]. PAPERS CONTRIBUTED TO THE 9TH INTERNATIONAL CONGRESS OF ANDROLOGY, 2009, : 47 - 52
  • [8] Hormonal male contraception
    Wang, Christina
    Meriggiola, Cristina
    Behre, Hermann M.
    Page, Stephanie T.
    [J]. ANDROLOGY, 2024, 12 (07) : 1551 - 1557
  • [9] Hormonal contraception in the male
    Anderson, RA
    [J]. BRITISH MEDICAL BULLETIN, 2000, 56 (03) : 717 - 728
  • [10] Male hormonal contraception
    Oxynos, C
    Wu, FCW
    [J]. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 14 (03) : 473 - 487